Dynavax Technologies reported $128.77M in EBITDA for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Agenus AGEN:US $ -43.28M 8.94M
Amgen AMGN:US $ 3004M 337M
AstraZeneca AZN:LN 292568.43M 24571.33M
Astrazeneca AZN:US $ 3562M 625M
Biogen BIIB:US $ 1075.7M 401M
Biomarin Pharmaceutical BMRN:US $ 64.42M 7.75M
Bristol Myers Squibb BMY:US $ 5780M 8M
Chimerix CMRX:US $ -23.42M 1.32M
Dynavax Technologies DVAX:US $ 128.77M 96.32M
Gilead Sciences GILD:US $ 2585M 837M
Glaxosmithkline GSK:US $ 2447M 673M
Idera Pharmaceuticals IDRA:US $ -5.36M 1.18M
Minerva Neurosciences NERV:US $ -6.96M 1.02M
Nektar Therapeutics NKTR:US $ -44.27M 67.08M
Neurocrine Biosciences NBIX:US $ 58.6M 52.2M
Novartis NOVN:VX SF 4660M 108M
Pfizer PFE:US $ 12921M 1739M
Regeneron Pharmaceuticals REGN:US $ 1381.3M 20.4M
Sarepta Therapeutics SRPT:US $ -201.24M 125.08M
Vertex Pharmaceuticals VRTX:US $ 1156.6M 87.3M